Also called: CJC 1295, CJC-1295 / Ipamorelin Combination, CJC-1295 & GHRP Combination
CJC-1295 is a man-made peptide, which is a tiny chain of building blocks called amino acids. It is made to tell the body to let out more growth hormone. Growth hormone is a natural body chemical that helps with muscle, energy, and repair. It is not an approved medicine.
It is mostly sold as a powder for lab research, and some clinics and wellness centers have used it for anti-aging and fitness goals. In the body, CJC-1295 works like a natural signal that nudges the pituitary gland, a small gland in the brain, to release growth hormone in steady pulses. It lasts a long time in the body, so it can keep the pulses going. People hope this may help with muscle, fat loss, sleep, and recovery.
But it does this indirectly — it asks the body to make more of its own hormone instead of giving the hormone directly. Much of what we know comes from early human studies and lab work, not large careful trials. Long-term safety is not well known, and side effects like water retention, numbness, and tiredness have been reported. In the United States, regulators moved CJC-1295 to a restricted list for compounding in 2023, so it is not legal to sell for human use. Anyone thinking about it should talk to a real doctor first.
Building Blocks
CJC-1295 is one of the building blocks in this blend or stack people actually buy:
Natural growth-hormone release — recovery, body composition, sleep
Paired with Ipamorelin
Established GH blend
Two Forms Exist
Both are valid research forms — they differ in how long they stay active. Neither is sold on its own here; each page shows the blend it comes in.
The longer-acting form of CJC-1295 — an extended-release GH secretagogue.
Half-life: ≈ 6–8 days (DAC extends it from minutes to days)
The short-acting form of CJC-1295 — a precise, injection-time GH pulse.
Half-life: ≈ 30 minutes (native-like Mod GRF 1-29 kinetics)
Benefits
The main themes across 20 research studies, in plain language.
Research suggests that the peptide may stimulate the release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), potentially elevating their levels in the body for extended periods.
Research indicates the peptide has an extended half-life and sustained activity due to mechanisms like albumin binding, allowing for less frequent dosing.
Evidence suggests that combining this peptide with other agents (like Ipamorelin) may activate dual pathways to produce a synergistic increase in growth hormone output.
Research indicates the peptide may selectively stimulate GH release without significantly elevating stress hormones like cortisol, prolactin, or ACTH.
Limited evidence suggests the peptide may support reproductive health by promoting ovulation and modulating hormonal axes like LH/FSH.
Research suggests the peptide may mimic or preserve the body's natural pulsatile secretion patterns of growth hormone, rather than causing a constant flat elevation.
Research suggests the peptide may support recovery from injuries and exercise by promoting protein synthesis, collagen production, and the repair of connective tissues.
Animal models suggest the peptide may support skeletal health by improving bone mineral density and normalizing growth.
Findings suggest the peptide may stimulate appetite, which can be relevant for conditions involving wasting or poor nutritional intake.
Some findings suggest the peptide may modulate immune system activity and reduce inflammatory tone in adipose tissue.
Studies indicate potential shifts in body mass, including the reduction of adipose tissue (particularly visceral fat) and the preservation or increase of lean muscle mass.
Studies suggest the peptide may influence metabolic markers, potentially promoting fat oxidation, improving insulin sensitivity, and favorably altering lipid profiles.
Preliminary research points to potential protective effects on the heart and kidneys, such as improving post-infarct remodeling and reducing renal stress.
Some studies suggest the peptide may influence the central nervous system, potentially improving executive function, verbal memory, and sexual arousal.
Findings imply that increased collagen synthesis could improve skin elasticity, hydration, and overall quality, as well as support joint and tendon health.
Evidence points to improvements in sleep patterns, specifically increases in slow-wave (deep) sleep and sleep duration, possibly linked to nocturnal GH release.
Studies note logistical and stability factors such as peptide solubility, storage requirements, and the reproducibility of experimental data.
See where CJC-1295 fits — the most-used combinations, dosing notes from the research, and what to check before you buy.
No spam. Unsubscribe anytime.
1 reported routine — each line links to the source it came from.
Self-reported & vendor-suggested
Routines shared by users and sellers in forums and product pages — anecdotal, not tested in clinical trials. We show them for completeness, not as a recommendation.
SubQ
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH). The Drug Affinity Complex (DAC) binds serum albumin, extending half-life to roughly a week and producing sustained, dose-dependent increases in GH (2-10x) and IGF-1 lasting days to weeks. It is not FDA-approved.
Evidence
Every claim above traces back to a source you can check — here are 10 of them.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.
CJC-1295 - AdisInsight
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Timeline
Key moments in CJC-1295’s research and regulatory timeline — sourced and dated.
News
Dated, sourced reporting that mentions CJC-1295.
Wondering how CJC-1295 pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Explore by goal
Related peptides
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.